Objective: Head and neck squamous cell carcinoma (HNSCC) is a debilitating disease which is cured only 50% of the time. If diagnosed early, survival rates could reach 80%, but there is currently no practical method for early detection. CD44 comprises a family of isoforms that, in certain tumors, are alternatively spliced and overexpressed in tissues and circulation. Here we examine salivary soluble CD44 (solCD44) expression in HNSCC patients and normal controls to determine its potential as a screening tool.
Method: We did a solCD44 ELISA on saliva from 26 HNSCC patients, 10 normal volunteers, conditioned media (CM) of 4 HNSCC cell lines, and 1 CD44-negative cell line (COS-7). Western blot was done on CM from 2 HNSCC cell lines (UMSS11B and FaDu), COS-7, 3 HNSCC, and 2 normal saliva specimens to verify ELISA antibody specificity. SolCD44 levels were significantly elevated in HNSCC patients compared with normal controls (7.85 ng/mL for HNSCC patients and 1.09 ng/mL for normal controls, P < 0.001).
Results: The test detected 79% of mucosally invasive HNSCC using preliminary cutoff points. SolCD44 levels did not vary significantly with tumor size, stage, recurrence, history of radiation treatment, or tobacco and alcohol risk factors. A 65 to 75 kDa band, corresponding to solCD44, was detected in all of the HNSCC cell line CM and saliva whereas normal samples showed a fainter band or were undetectable.
Conclusion: In this preliminary analysis, the salivary solCD44 ELISA seems to effectively detect HNSCC at all stages. Further study is indicated because early detection is clearly important in this disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1055-9965.EPI-04-0546 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
Oral Oncol
January 2025
Value and Implementation, Outcomes Research, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
Background: Pembrolizumab with/without platinum + 5-FU is approved for the first-line (1L) treatment of R/M HNSCC, and its monotherapy use requires PD-L1 Combined Positive Score (CPS) ≥ 1. We aimed to understand PD-L1 testing patterns and associations with patient characteristics and treatment choice in R/M HNSCC.
Methods: Adults with R/M HNSCC initiating 1L systemic therapy were included from a U.
Analysis of nuclear receptor expression in head and neck cancer.
Cancer Genet
December 2024
Department of Otolaryngology, University of Minnesota, MMC396, 420 Delaware St SE, Minneapolis, MN 55455, USA.
Objective: Studies of squamous cell carcinoma of the head and neck (HNSCC) have demonstrated the importance of nuclear receptors and their associated coregulators in the development and treatment of HNSCC. We sought to characterize members of the nuclear receptor super family through interrogation of RNA-Seq and microarray data.
Materials And Methods: TCGA RNA-Seq data within the cBioportal platform comparing HNSCC samples (n = 515 patients with RNA-Seq data) to normal tissue (n = 82 patients) was interrogated for significant differences in nuclear receptor expression.
Lymph Node Yield/Ratio, Neutrophil-Lymphocyte Ratio: Prognostic Factors in cN0 Laryngeal Carcinoma.
Laryngoscope
January 2025
Department of Otolaryngology - Head and Neck Surgery, Mansoura University, Mansoura, Egypt.
Objectives: The aim of this study was to investigate the role of lymph node yield (LNY), lymph node ratio (LNR), and neutrophil to lymphocyte ratio (NLR) as prognostic factors, their impact on survival in patients with advanced laryngeal squamous cell carcinoma (LSCC).
Methods: This multicentric retrospective study included 195 patients with clinical N0 advanced laryngeal carcinoma who underwent total laryngectomy and/or total pharyngolaryngectomy over 5 years. The number of lymph nodes extracted (LNY) and the number of positive nodes were counted.
The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study.
World J Surg Oncol
January 2025
Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China.
Objective: This study aims to elucidate the therapeutic efficacy and safety of a taxane-based chemotherapy in combination with immune checkpoint inhibitors regimen in patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Methods: We retrospectively collected clinical data from 154 patients who received at least two cycles of PD-1 inhibitors in combination with a taxane-based chemotherapy as first-line treatment in seven hospitals in Hunan Province, between December 2018 and December 2023. These patients were subjected to long-term follow-up.
Lymph node metastasis in level IIb neck dissection for clinically node-negative oral squamous cell carcinoma patients: an 11-year retrospective study.
Int J Oral Maxillofac Surg
January 2025
Service de Chirurgie Maxillo-Faciale et Stomatologie, Université de Bordeaux, CHU Bordeaux, Bordeaux, France. Electronic address:
The most common complication associated with selective neck dissection is spinal accessory nerve dysfunction and shoulder disability, which result from level IIb dissection. The main objective of this study was to evaluate the incidence of level IIb lymph node metastasis in clinically node-negative (cN0) oral squamous cell carcinoma (OSCC) patients. Patients presenting with cN0 OSCC between November 2012 and November 2023 were included retrospectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!